TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 1 of 13
Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
PRODUCT NAME
TRIPLE SULFA POWDER MEDICATION
STATEMENT OF HAZARDOUS NATURE
CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR
1910.1200.
SUPPLIER
Company: Aquarium Pharmaceuticals Incorporated
Address:
50 East Hamilton Street
Chalfont
PA, 18914
USA
Telephone: +1 215 822 8181
Fax: +1 215 822 1906
PRODUCT USE
Used according to manufacturers directions.
SYNONYMS
Section 2 - COMPOSITION / INFORMATION ON INGREDIENTS
NAME CAS RN %
sodium chloride 7647-14-5 >60
sulfathiazole, sodium salt 144-74-1 10-30
sulfamethazine 57-68-1 1-10
sulfacetamide sodium 127-56-0 1-10
silica amorphous, fumed, crystalline free 112945-52-5 1-5
Section 3 - HAZARDS IDENTIFICATION
CANADIAN WHMIS SYMBOLS
EMERGENCY OVERVIEW
RISK
POTENTIAL HEALTH EFFECTS
ACUTE HEALTH EFFECTS
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 2 of 13
Section 3 - HAZARDS IDENTIFICATION
SWALLOWED
Accidental ingestion of the material may be damaging to the health of the
individual.
Sulfonamides and their derivatives can cause extensive kidney damage, and
destroy red blood cells. Overdose may cause an accumulation of acid in the blood
or a diminished blood sugar level with confusion and coma resulting. Predisposed
persons can develop hypersensitivity reactions, including for topical
application. Deaths have occurred due to hypersensitivity, anemia, imbalances in
blood cell distribution and kidney and liver damage. 2-5 grams can be fatal.
Sulfonamides cross the placental barrier, are excreted in the breast milk and
may produce adverse effects in the fetus/ embryo and newborn, including loss of
certain white blood cells causing immune function deficiency, anemia, jaundice
and kernicterus.
EYE
There is some evidence that material may produce eye irritation in some persons
and produce eye damage 24 hours or more after instillation. Moderate
inflammation may be expected with redness; conjunctivitis may occur with
prolonged exposure.
Eye drops with sulfonamides can cause local irritation, sensations of burning
and stinging, blurred vision and loss of depth perception. The conjunctiva and
cornea may become inflamed, and the cornea and lens may become clouded.
SKIN
There is some evidence to suggest that the material may cause mild but
significant inflammation of the skin either following direct contact or after a
delay of some time. Repeated exposure can cause contact dermatitis which is
characterized by redness, swelling and blistering.
Entry into the blood-stream, through, for example, cuts, abrasions or lesions,
may produce systemic injury with harmful effects. Examine the skin prior to the
use of the material and ensure that any external damage is suitably protected.
INHALED
Inhalation may produce health damage*.
Inhalation of dusts, generated by the material during the course of normal
handling, may be damaging to the health of the individual.
CHRONIC HEALTH EFFECTS
Long term exposure to high dust concentrations may cause changes in lung
function i.e. pneumoconiosis; caused by particles less than 0.5 micron
penetrating and remaining in the lung. Prime symptom is breathlessness; lung
shadows show on X-ray. There has been some concern that this material can cause
cancer or mutations but there is not enough data to make an assessment. There is
some evidence to provide a presumption that human exposure to the material may
result in impaired fertility on the basis of: some evidence in animal studies of
impaired fertility in the absence of toxic effects, or evidence of impaired
fertility occurring at around the same dose levels as other toxic effects but
which is not a secondary non-specific consequence of other toxic effects.
Exposure to the material may cause concerns for humans owing to possible
developmental toxic effects, on the basis that similar materials tested in
appropriate animal studies provide some suspicion of developmental toxicity in
the absence of signs of marked maternal toxicity, or at around the same dose
levels as other toxic effects but which are not a secondary non-specific
consequence of other toxic effects. Prolonged oral treatment with sulfonamides
has caused nausea, vomiting, diarrhea, abdominal pain, loss of appetite,
inflammation of the mouth cavity, impaired folic acid absorption, exacerbation
of porphyria, acidosis, liver damage with impaired blood clotting, jaundice and
inflammation of the pancreas. Effects on the kidney include blood and crystals
in the urine, painful and frequent urination or lack of urine with nitrogen
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 3 of 13
Section 3 - HAZARDS IDENTIFICATION
retention. Nervous system symptoms include headache, drowsiness, trouble
sleeping, dizziness, ringing in the ears, hearing loss, depression,
hallucinations, inco-ordination, paralysis of muscles, numbness in the
extremities, spinal cord damage and inflammation, convulsions and
unconsciousness. Effects on the blood includes a change in blood cell
distribution with loss of white blood cells and platelets, and anemia, which
Africans seem to be more prone to developing than Europeans. Cyanosis can occur
owing to complexes being formed by hemoglobin. Eye effects include inflamed
cornea and conjunctiva with eyelid swelling and in severe cases, fear of the
light. Allergies and cross-sensitivity is common, and can cause itches, wheals
and sometimes a severe red rash with blisters that is often fatal. This class of
drugs can scar the cornea and conjunctiva, swelling around the eyes, painful and
inflamed joints, reduced sperm counts, pneumonia, fever, chills, hair loss,
inflammation of vessels, lupus, reduced lung function, infertility,
hypothyroidism and goiter, and increased urinary output. More seriously, the
lungs may become permanently scarred and there may be irreversible damage to the
nervous system and muscles. Inflammation of the skin has occurred after the drug
is ingested and has traveled through the bloodstream. Skin effects often occur
when there has been exposure in conjunction with UV light. Clothed areas are
initially less likely to be affected but may be in later stages. Rarely there
may be persistence of inflammation on light contact even after the drug has been
removed.
Section 4 - FIRST AID MEASURES
SWALLOWED
鈥? For advice, contact a Poisons Information Center or a doctor at once.
鈥? Urgent hospital treatment is likely to be needed.
鈥? If swallowed do NOT induce vomiting.
鈥? If vomiting occurs, lean patient forward or place on left side (head-down
position, if possible) to maintain open airway and prevent aspiration.
鈥? Observe the patient carefully.
鈥? Never give liquid to a person showing signs of being sleepy or with reduced
awareness; i.e. becoming unconscious.
鈥? Give water to rinse out mouth, then provide liquid slowly and as much as
casualty can comfortably drink.
鈥? Transport to hospital or doctor without delay.
EYE
If this product comes in contact with the eyes:
鈥? Wash out immediately with fresh running water.
鈥? Ensure complete irrigation of the eye by keeping eyelids apart and away from
eye and moving the eyelids by occasionally lifting the upper and lower lids.
鈥? If pain persists or recurs seek medical attention.
鈥? Removal of contact lenses after an eye injury should only be undertaken by
skilled personnel.
SKIN
If skin contact occurs:
鈥? Immediately remove all contaminated clothing, including footwear
鈥? Flush skin and hair with running water (and soap if available).
鈥? Seek medical attention in event of irritation.
INHALED
鈥? If fumes or combustion products are inhaled remove from contaminated area.
鈥? Lay patient down. Keep warm and rested.
鈥? Prostheses such as false teeth, which may block airway, should be removed,
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 4 of 13
Section 4 - FIRST AID MEASURES
where possible, prior to initiating first aid procedures.
鈥? Apply artificial respiration if not breathing, preferably with a demand valve
resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if
necessary.
鈥? Transport to hospital, or doctor.
NOTES TO PHYSICIAN
Treat symptomatically.
In cases of recent sulfonamide overdose the stomach should be emptied by
aspiration and lavage. If kidney function is adequate, a saline purgative, such
as sodium sulfate, 30 g in 250 ml water, may be given to promote peristalsis and
elimination of sulfonamide in the urine may be assisted by giving alkalis, such
as sodium bicarbonate and increasing fluid intake. Severe crystalluria may
require ureteric catheterization and irrigation with warm 2.5% sodium
bicarbonate solution. Treatment should be continued until it can be assumed that
the sulfonamide has been eliminated. The majority of sulfonamides are
metabolized to acetylated derivatives which retain the toxicity of the parent
compound and thus may indicate more active removal when adverse effects are very
severe. Active measures may include forced diuresis, peritoneal dialysis and
charcoal hemoperfusion.
[Martindale: The Extra Pharmacopoeia, 28th Ed.].
Section 5 - FIRE FIGHTING MEASURES
Flash Point (掳 Not Applicable
F):
Lower Explosive Limit (%): Not Applicable
Upper Explosive Limit (%): Not Applicable
Autoignition Temp (掳 Not Applicable
F):
EXTINGUISHING MEDIA
鈥? There is no restriction on the type of extinguisher which may be used.
Use extinguishing media suitable for surrounding area.
FIRE FIGHTING
鈥? Alert Emergency Responders and tell them location and nature of hazard.
鈥? Wear breathing apparatus plus protective gloves for fire only.
鈥? Prevent, by any means available, spillage from entering drains or water
course.
鈥? Use fire fighting procedures suitable for surrounding area.
鈥? Do not approach containers suspected to be hot.
鈥? Cool fire exposed containers with water spray from a protected location.
鈥? If safe to do so, remove containers from path of fire.
鈥? Equipment should be thoroughly decontaminated after use.
GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS
鈥? Solid which exhibits difficult combustion or is difficult to ignite.
鈥? Avoid generating dust, particularly clouds of dust in a confined or
unventilated space as dusts may form an explosive mixture with air, and any
source of ignition, i.e. flame or spark, will cause fire or explosion. Dust
clouds generated by the fine grinding of the solid are a particular hazard;
accumulations of fine dust may burn rapidly and fiercely if ignited.
鈥? Dry dust can be charged electrostatically by turbulence, pneumatic transport,
pouring, in exhaust ducts and during transport.
鈥? Build-up of electrostatic charge may be prevented by bonding and grounding.
鈥? Powder handling equipment such as dust collectors, dryers and mills may
require additional protection measures such as explosion venting.
Combustion products include.
Decomposition may produce toxic fumes of, carbon dioxide (CO2), hydrogen
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 5 of 13
Section 5 - FIRE FIGHTING MEASURES
chloride, phosgene, nitrogen oxides (NOx), sulfur oxides (SOx), metal oxides,
other pyrolysis products typical of burning organic material.
May emit poisonous fumes.
May emit corrosive fumes.
FIRE INCOMPATIBILITY
Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids,
chlorine bleaches, pool chlorine etc. as ignition may result.
PERSONAL PROTECTION
Glasses:
Chemical goggles.
Gloves:
PVC chemical resistant type.
Respirator:
Particulate
Section 6 - ACCIDENTAL RELEASE MEASURES
MINOR SPILLS
鈥? Remove all ignition sources.
鈥? Clean up all spills immediately.
鈥? Avoid contact with skin and eyes.
鈥? Control personal contact by using protective equipment.
鈥? Use dry clean up procedures and avoid generating dust.
鈥? Place in a suitable labelled container for waste disposal.
MAJOR SPILLS
Moderate hazard.
鈥? CAUTION: Advise personnel in area.
鈥? Alert Emergency Responders and tell them location and nature of hazard.
鈥? Control personal contact by wearing protective clothing.
鈥? Prevent, by any means available, spillage from entering drains or water
courses.
鈥? Recover product wherever possible.
鈥? IF DRY: Use dry clean up procedures and avoid generating dust. Collect
residues and place in sealed plastic bags or other containers for disposal. IF
WET: Vacuum/shovel up and place in labelled containers for disposal.
鈥? ALWAYS: Wash area down with large amounts of water and prevent runoff into
drains.
鈥? If contamination of drains or waterways occurs, advise emergency services.
EMERGENCY RESPONSE PLANNING GUIDELINES (ERPG)
The maximum airborne concentration below which it is believed that nearly all
individuals could be exposed for up to one hour WITHOUT experiencing or developing
life-threatening health effects is:
sodium chloride 500 mg/m鲁
irreversible or other serious effects or symptoms which could
impair an individual's ability to take protective action is:
sodium chloride 300 mg/m鲁
other than mild, transient adverse effects
without perceiving a clearly defined odour is:
sodium chloride 40 mg/m鲁
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 6 of 13
Section 6 - ACCIDENTAL RELEASE MEASURES
The threshold concentration below which most people.
will experience no appreciable risk of health effects:
sodium chloride 15 mg/m鲁
American Industrial Hygiene Association (AIHA)
Ingredients considered according to the following cutoffs
Very Toxic (T+) >= 0.1% Toxic (T) >= 3.0%
R50 >= 0.25% Corrosive (C) >= 5.0%
R51 >= 2.5%
else >= 10%
where percentage is percentage of ingredient found in the mixture
Section 7 - HANDLING AND STORAGE
PROCEDURE FOR HANDLING
鈥? Avoid all personal contact, including inhalation.
鈥? Wear protective clothing when risk of exposure occurs.
鈥? Use in a well-ventilated area.
鈥? Prevent concentration in hollows and sumps.
鈥? DO NOT enter confined spaces until atmosphere has been checked.
鈥? DO NOT allow material to contact humans, exposed food or food utensils.
鈥? Avoid contact with incompatible materials.
鈥? When handling, DO NOT eat, drink or smoke.
鈥? Keep containers securely sealed when not in use.
鈥? Avoid physical damage to containers.
鈥? Always wash hands with soap and water after handling.
鈥? Work clothes should be laundered separately.
鈥? Launder contaminated clothing before re-use.
鈥? Use good occupational work practice.
鈥? Observe manufacturer's storing and handling recommendations.
鈥? Atmosphere should be regularly checked against established exposure standards
to ensure safe working conditions are maintained.
RECOMMENDED STORAGE METHODS
鈥? Polyethylene or polypropylene container.
鈥? Check all containers are clearly labelled and free from leaks.
STORAGE REQUIREMENTS
Observe manufacturer's storing and handling recommendations.
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
EXPOSURE CONTROLS
Source Material TWA TWA STEL STEL Peak Peak
ppm mg/m鲁 ppm m5/m鲁 ppm mg/m鲁
_________________________ ________________ _____ _____ _____ _____ _____ _____
Canada - Saskatchewan sodium chloride 3 6
Occupational Health and
Safety Regulations -
Contamination Limits
Canada - Saskatchewan sodium chloride 10 20
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 7 of 13
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
Source Material TWA TWA STEL STEL Peak Peak
ppm mg/m鲁 ppm m5/m鲁 ppm mg/m鲁
_________________________ ________________ _____ _____ _____ _____ _____ _____
Occupational Health and
Safety Regulations -
Contamination Limits
Canada - Saskatchewan sulfamethazine 3 6
Occupational Health and
Safety Regulations -
Contamination Limits
Canada - Saskatchewan sulfamethazine 10 20
Occupational Health and
Safety Regulations -
Contamination Limits
Canada - Saskatchewan sulfacetamide 3 6
Occupational Health and sodium
Safety Regulations -
Contamination Limits
Canada - Saskatchewan sulfacetamide 10 20
Occupational Health and sodium
Safety Regulations -
Contamination Limits
The following materials had no OELs on our record under the following CAS or Chemwatch (CW) numbers
Triple Sulfa Powder Medication: No data available for CW:4658-80
sodium chloride: No data available for CAS:7647-14-5
sulfathiazole, sodium salt: No data available for CAS:144-74-1 CAS:6791-71-5 CAS:72-14-0
sulfamethazine: No data available for CAS:57-68-1
sulfacetamide sodium: No data available for CAS:127-56-0 CAS:6209-17-2
silica amorphous, fumed, crystalline free: No data available for CAS:112945-52-5 CAS:67256-35-3
EMERGENCY EXPOSURE LIMITS
Material Original IDLH Original IDLH Revised IDLH R
Value (ppm) Value (mg/m3) Value (mg/m3) V
silica amorphous, fumed, crystalline free N.E. N.E. 3,000
Not available. Refer to individual constituents.
EXPOSURE STANDARDS FOR MIXTURE
"Worst Case" computer-aided prediction of spray/ mist or fume/ dust components
and concentration:
Composite Exposure Standard for Mixture (TWA) :2 mg/m鲁.
Operations which produce a spray/mist or fume/dust, introduce particulates to
the breathing zone.
If the breathing zone concentration of ANY of the components listed below is
exceeded, "Worst Case" considerations deem the individual to be overexposed.
Component Breathing Zone ppm Breathing Zone mg/m鲁 Mixture Conc (%).
Component Breathing Zone Mixture Conc
(mg/m鲁) (%)
silica amorphous, fumed, crystalli 2.0000 5.0
INGREDIENT DATA
SODIUM CHLORIDE:
Not available. Refer to individual constituents.
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 8 of 13
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
For each of the following
SULFATHIAZOLE, SODIUM SALT:
SULFAMETHAZINE:
SULFACETAMIDE SODIUM:
Airborne particulate or vapor must be kept to levels as low as is practicably
achievable given access to modern engineering controls and monitoring hardware.
Biologically active compounds may produce idiosyncratic effects which are
entirely unpredictable on the basis of literature searches and prior clinical
experience (both recent and past).
SILICA AMORPHOUS, FUMED, CRYSTALLINE FREE:
TLV TWA: 2 mg/m鲁
ES TWA: 2 mg/m鲁
PERSONAL PROTECTION
EYE
鈥? Safety glasses with side shields.
鈥? Chemical goggles.
鈥? Contact lenses pose a special hazard; soft lenses may absorb irritants and all
lenses concentrate them. DO NOT wear contact lenses.
HANDS/FEET
Experience indicates that the following polymers are suitable as glove materials
for protection against undissolved, dry solids.
鈥? polychloroprene
鈥? nitrile rubber
鈥? butyl rubber
鈥? fluorocaoutchouc
鈥? polyvinyl chloride
Gloves should be examined for wear and/ or degradation constantly.
Wear chemical protective gloves, eg. PVC.
Wear safety footwear or safety gumboots, eg. Rubber.
OTHER
鈥? Overalls.
鈥? P.V.C. apron.
鈥? Barrier cream.
鈥? Skin cleansing cream.
鈥? Eye wash unit.
RESPIRATOR
Protection Factor Half-Face Full-Face Powered Air
Respirator Respirator Respirator
10 x PEL P1 - PAPR-P1
Air-line* - -
50 x PEL Air-line** P2 PAPR-P2
100 x PEL - P3 -
Air-line* -
100+ x PEL - Air-line** PAPR-P3
* - Negative pressure demand ** - Continuous flow
Explanation of Respirator Codes:
Class 1 low to medium absorption capacity filters.
Class 2 medium absorption capacity filters.
Class 3 high absorption capacity filters.
PAPR Powered Air Purifying Respirator (positive pressure) cartridge.
Type A for use against certain organic gases and vapors.
Type AX for use against low boiling point organic compounds (less than
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 9 of 13
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
65ºC).
Type B for use against certain inorganic gases and other acid gases and vapors.
Type E for use against sulfur dioxide and other acid gases and vapors.
Type K for use against ammonia and organic ammonia derivatives
Class P1 intended for use against mechanically generated particulates of sizes
most commonly encountered in industry, e.g. asbestos, silica.
Class P2 intended for use against both mechanically and thermally generated
particulates, e.g. metal fume.
Class P3 intended for use against all particulates containing highly toxic
materials, e.g. beryllium.
The local concentration of material, quantity and
conditions of use determine the type of personal
protective equipment required.
Use appropriate NIOSH-certified respirator based on informed professional
judgement. In conditions where no reasonable estimate of exposure can be
made, assume the exposure is in a concentration IDLH and use NIOSH-certified
full face pressure demand SCBA with a minimum service life of 30 minutes, or
a combination full facepiece pressure demand SAR with auxiliary self-contained
air supply. Respirators provided only for escape from IDLH atmospheres shall be
NIOSH-certified for escape from the atmosphere in which they will be used.
ENGINEERING CONTROLS
Unless written procedures, specific to the workplace are available, the
following is intended as a guide:
鈥? For Laboratory-scale handling of Substances assessed to be toxic by
inhalation. Quantities of up to 25 grams may be handled in Class II biological
safety cabinets *; Quantities of 25 grams to 1 kilogram may be handled in Class
II biological safety cabinets* or equivalent containment systems Quantities
exceeding 1 kg may be handled either using specific containment, a hood or Class
II biological safety cabinet*,
鈥? HEPA terminated local exhaust ventilation should be considered at point of
generation of dust, fumes or vapors.
鈥? The need for respiratory protection should also be assessed where incidental
or accidental exposure is anticipated. Dependent on levels of contamination,
PAPR, full face air purifying devices with P2 or P3 filters or air supplied
respirators should be evaluated. When handling: Quantities of up to 25 grams, an
approved respirator with HEPA filters or cartridges should be considered
Quantities of 25 grams to 1 kilogram, a half-face negative pressure, full
negative pressure, or powered helmet-type air purifying respirator should be
considered. Quantities in excess of 1 kilogram, a full face negative pressure,
helmet-type air purifying, or supplied air respirator should be considered.
Written procedures, specific to a particular work-place, may replace these
recommendations
* For Class II Biological Safety Cabinets, Types B2 or B3 should be considered.
Where only Class I, open fronted Cabinets are available, glove panels may be
added, Laminar flow cabinets do not provide sufficient protection when handling
these materials unless especially designed to do so.
Local exhaust ventilation usually required. If risk of overexposure exists, wear
an approved respirator. Correct fit is essential to obtain adequate protection
an approved self contained breathing apparatus (SCBA) may be required in some
situations. Provide adequate ventilation in warehouse or closed storage area.
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 10 of 13
Section 9 - PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL PROPERTIES
Mixes with water.
Molecular Weight: Not Applicable Boiling Range (掳 Not Ap plicable
C):
Melting Range (掳 Not Applicable
C): Specific Gravity (water =1): 1.01
Solubility in water (g/L): Miscible pH (as supplied): Not Applicable
pH (1% solution): Not Applicable Vapor Pressure (kPa): Not Applicable
Volatile Component (%vol): Not Applicable Evaporation Rate: Not Applicable
Relative Vapor Density (air=1): Not Applicable Flash Point (掳 Not Applicable
C):
Lower Explosive Limit (%): Not Applicable Upper Explosive Limit (%): Not Applicable
Autoignition Temp (掳 Not Applicable
C): Decomposition Temp (掳 Not Available
C):
State: Divided Solid Viscosity: Not Applicable
APPEARANCE
White powder with no odour; soluble in water.
Section 10 - CHEMICAL STABILITY AND REACTIVITY INFORMATION
CONDITIONS CONTRIBUTING TO INSTABILITY
鈥? Presence of incompatible materials.
鈥? Product is considered stable.
鈥? Hazardous polymerization will not occur.
STORAGE INCOMPATIBILITY
Avoid strong acids, bases.
Avoid reaction with oxidizing agents.
Section 11 - TOXICOLOGICAL INFORMATION
Triple Sulfa Powder Medication
Not available. Refer to individual constituents.
unless otherwise specified data extracted from RTECS - Register of Toxic Effects
of Chemical Substances
SODIUM CHLORIDE:
TOXICITY IRRITATION
Oral (rat) LD50: 3000 mg/kg Skin (rabbit): 500 mg/24h - Mild
Oral (human) TDLo: 12357 mg/kg/23d Eye (rabbit): 10 mg - Moderate
Oral Lowest Toxic Dose (Human): 8.2 mg/kg Eye
(rabbit):100 mg/24h - Moderate
SULFATHIAZOLE, SODIUM SALT:
TOXICITY IRRITATION
Oral (Mouse) LD50: 3800 mg/kg
Intraperitoneal (Mouse) LD50: 1320 mg/kg
Subcutaneous (Mouse) LD50: 1434 mg/kg
Intravenous (Mouse) LD50: 708 mg/kg
No significant acute toxicological data identified in literature search.
NOTE: Substance has been shown to be mutagenic in at least one assay, or belongs
to a family of chemicals producing damage or change to cellular DNA.
Bacterial cell mutagen
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 11 of 13
Section 11 - TOXICOLOGICAL INFORMATION
Equivocal tumorigen by RTECS criteria
SULFAMETHAZINE:
TOXICITY IRRITATION
Subcutaneous (rat) LD50: 2000 mg/kg Nil Reported
Oral (mouse) LD50: 50000 mg/kg
Intraperitoneal (mouse) LD50: 1060 mg/kg
Subcutaneous (mouse) LD50: 1440 mg/kg
Intravenous (mouse) LD50: 1776 mg/kg
Intravenous (rabbit) LD50: 2450 mg/kg
Inhalation (guinea) pig: LC50 770 ppm/4h
Somnolence, dyspnea recorded.
The substance is classified by IARC as Group 3:
NOT classifiable as to its carcinogenicity to humans.
Evidence of carcinogenicity may be inadequate or limited in animal testing.
SULFACETAMIDE SODIUM:
TOXICITY IRRITATION
Subcutaneous (mouse) LD50: 6000 mg/kg Nil Reported
Intraperitoneal (mouse) LD50: 974 mg/kg
Yeast cell mutagen
SILICA AMORPHOUS, FUMED, CRYSTALLINE FREE:
TOXICITY IRRITATION
Oral (rat) LD50: 3160 mg/kg No data
Dermal (rabbit) LD50: >5000 mg/kg * * [Cabot]
Section 12 - ECOLOGICAL INFORMATION
DO NOT discharge into sewer or waterways.
Refer to data for ingredients, which follows:
SODIUM CHLORIDE:
TLm 96 > 1000 ppm
SULFATHIAZOLE, SODIUM SALT:
DO NOT discharge into sewer or waterways.
SULFAMETHAZINE:
"log Kow (Sangster 1997):" 0.28
DO NOT discharge into sewer or waterways.
SULFACETAMIDE SODIUM:
DO NOT discharge into sewer or waterways.
SILICA AMORPHOUS, FUMED, CRYSTALLINE FREE:
Zebra fish LC50(96hr): 10000 mg/L.
Daphnia magna LC50(24hr): 10000 mg/L.
No adverse effects on water purification plant if removed mechanically.
Section 13 - DISPOSAL CONSIDERATIONS
Disposal Instructions
All waste must be handled in accordance with local, state and federal
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 12 of 13
Section 13 - DISPOSAL CONSIDERATIONS
regulations.
鈥? Recycle wherever possible.
鈥? Consult manufacturer for recycling options or consult Waste Management
Authority for disposal if no suitable treatment or disposal facility can be
identified.
鈥? Dispose of by: Burial in a licensed land-fill or Incineration in a licensed
apparatus (after admixture with suitable combustible material)
鈥? Decontaminate empty containers. Observe all label safeguards until containers
are cleaned and destroyed.
Section 14 - TRANSPORTATION INFORMATION
NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS:UN,IATA,IMDG
Section 15 - REGULATORY INFORMATION
RISK
None under normal operating conditions.
REGULATIONS
sodium chloride (CAS: 7647-14-5) is found on the following regulatory lists;
sulfathiazole, sodium salt (CAS: 144-74-1) is found on the following regulatory
lists;
sulfamethazine (CAS: 57-68-1) is found on the following regulatory lists;
sulfacetamide sodium (CAS: 127-56-0) is found on the following regulatory lists;
sulfacetamide sodium (CAS: 6209-17-2) is found on the following regulatory
lists;
silica amorphous, fumed, crystalline free (CAS: 112945-52-5) is found on the
following regulatory lists;
No data available for sulfathiazole, sodium salt as CAS: 6791-71-5.
No data available for silica amorphous, fumed, crystalline free as CAS:
67256-35-3.
Section 16 - OTHER INFORMATION
LIMITED EVIDENCE
Inhalation and/or ingestion may produce health damage*.
May produce discomfort of the eyes and skin*.
Limited evidence of a carcinogenic effect*.
May affect fertility*.
May possibly be harmful to the foetus/ embryo*.
* (limited evidence).
Denmark Advisory list for selfclassification of dangerous substances
Substance CAS Suggested codes
sulfathiazole, sodium salt 144-74-1 R43
sulfacetamide sodium 127-56-0 R43
sulfacetamide sodium 6209-17-2 R43
continued...
TRIPLE SULFA POWDER MEDICATION
Chemwatch Material Safety Data Sheet
Issue Date: 9-Jan-2006 CHEMWATCH 4658-80
B293EC CD 2006/1 Page 13 of 13
Section 16 - OTHER INFORMATION
INGREDIENTS WITH MULTIPLE CAS NUMBERS
Ingredient Name CAS
sulfathiazole, 144-74-1, 6791-71-5
sodium salt
sulfacetamide sodium 127-56-0, 6209-17-2
silica amorphous, 112945-52-5, 67256-35-3
fumed, crystalline
free
Reasonable care has been taken in the preparation of this information, but the
author makes no warranty of merchantability or any other warranty, expressed or
implied, with respect to this information. The author makes no representations
and assumes no liability for any direct, incidental or consequential damages
resulting from its use. For additional technical information please call our
toxicology department on +800 CHEMCALL.
Issue Date: 9-Jan-2006
Print Date: 21-Apr-2006
This document is copyright. Apart from any fair dealing for the purposes of
private study, research, review or criticism, as permitted under the Copyright
Act, no part may be reproduced by any process without written permission from
CHEMWATCH. TEL (+61 3) 9572 4700.
|